MAZE Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
-100.0%
20.0M
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
-100.0%
20.0M
0
0
0
Operating Expenses
48.0M
+3.2%
46.6M
+22.3%
38.1M
+15.5%
33.0M
-9.6%
36.5M
R&D
34.9M
+2.3%
34.1M
+23.9%
27.6M
+9.4%
25.2M
-10.4%
28.1M
SG&A
13.1M
+5.6%
12.4M
+18.3%
10.5M
+34.9%
7.8M
-7.1%
8.4M
Operating Income
-48035000
-80.9%
-26553000
+30.2%
-38059000
-15.5%
-32965000
+9.6%
-36474000
EBITDA
-47644000
-82.5%
-26109000
+30.5%
-37560000
-15.9%
-32394000
+9.6%
-35825000
Net Income
-44727000
-84.8%
-24208000
+30.0%
-34568000
-14.9%
-30087000
+10.7%
-33679000
EPS (Basic)
$-0.76
-68.9%
$-0.45
+29.7%
$-0.64
+3.0%
$-0.66
+14.3%
$-0.77
EPS (Diluted)
$-0.76
-68.9%
$-0.45
+29.7%
$-0.64
+3.0%
$-0.66
+14.3%
$-0.77
Shares (Diluted)
59.0M
+9.5%
53.9M
+0.4%
53.7M
+17.3%
45.8M
+4.5%
43.8M
Maze Therapeutics (MAZE) โ€” Financials